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Background: The aim of this study was to investigate the discor-
dance rates of eight known driver mutations among multiple matched 
intrapulmonary ground-glass nodules (GGNs) in non–small-cell 
lung cancer (NSCLC) patients.
Methods: Tumors from 35 patients with multiple lesions resected, 
including confirmed NSCLC and at least one GGN, were analyzed 
for mutations in EGFR, KRAS, HER2, BRAF, and PIK3CA together 
with fusions in ALK, ROS1, and RET.
Results: From 35 patients, a total of 72 lesions (60 were GGNs) were 
analyzed. These included nine adenocarcinoma in situ, nine minimal 
invasive adenocarcinoma, and 54 invasive adenocarcinoma. Among 
them, 33 tumor lesions (45.8 %) were found harboring EGFR muta-
tions: 13 tumors with exon 19 deletion, 18 with L858R on exon 21, 
and two with both exon 19 del and L858R mutation. There were 5 
tumors (6.9 %) harboring EML4-ALK fusion, four HER2 mutations 
(5.6%), three KRAS mutations (4.2%), one ROS1 fusion and one 
BRAF mutation. When we used the matched tumors to determine the 
intertumor discrepancy, only six out of 30 patients harbored identical 
mutations. The discordance rate of driver mutations was 80% (24 
of 30) in those patients harboring at least one of the detected driver 
mutations. The median disease-free survival was 41.2 months (95% 
confidence interval: 35.8–52.6 months) and the median overall sur-
vival was “still not reached” in this cohort.
Conclusions: We found a high discrepancy of driver mutations 
among NSCLC patients with GGNs and a favorable prognosis after 
multiple lesions resection, which support surgical resection in this 
situation as a reasonable approach.
Key Words: non–small-cell lung cancer, GGN, driver mutation, 
intertumor discrepancy.
(J Thorac Oncol. 2015;10: 778–783)
Synchronous multiple primary lung cancer (SMPLC), defined as multiple primary lung cancer discovered around 
same period of time,1,2 was reported to be rare with an inci-
dence ranging up to 0.5%.3 Although it has been difficult to 
distinguish SMPLC from metastatic disease,4 the application 
of molecular markers is now offering valuable information 
(reference here).4,5
With recent advances in diagnostic imaging modalities 
and the widespread use of chest computed tomography screen-
ing for high-risk individuals, pure ground-glass opacity (GGO) 
lesions or mixed ground-glass nodules (GGNs) have been 
increasingly detected on high-resolution computed tomography 
scans.6,7 Several studies have shown that patients with GGN 
have different clinical features or prognosis.8–10 It was thought 
the multifocality of lung nodules may be because of either the 
dissemination of malignant cells from a single primary tumor 
(intrapulmonary spread) or synchronous development of mul-
tifocal independent lesions.11,12 More importantly, several stud-
ies found that intertumor heterogeneity occurs in several types 
of solid tumors,11,13–19 which could be helpful to distinguish 
SMPLC from metastastic tumors because lesions with high 
heterogeneity likely arise from different tumor clones.5
To determine the clonal heterogeneity of such intra-
pulmonary GGNs, we examined 72 pulmonary nodules with 
the majority of them being GGN lesions from 35 patients to 
analyze mutational status of EGFR, KRAS, HER2, BRAF, and 
PIK3CA together with gene fusions in ALK, ROS1, and RET. 
In addition, we also provided here the follow-up results of 
those patients to demonstrate surgical resection could be as a 
rational approach in managing those GGN lesions.
MATERIALS AND METHODS
Patient’s Collection
Eligible patients were those non–small-cell lung cancer 
(NSCLC) patients who had multiple intrapulmonary nodules 
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with at least one grass ground nodule, and all lesions had to 
be resected. GGN was defined as hazy increased opacities of 
the lung with preservation of bronchial and vascular margins, 
including pure GGNs and part-solid GGNs. Tumor tissues 
were collected within 1 hour of resection and paraffin-embed-
ded. All cases were reviewed by pathologists for the confirma-
tion of tumor histology and tumor content. The histology was 
based on the criteria of the World Health Organization and 
the new classification of pulmonary adenocarcinoma.20 The 
TNM stage was determined according to version 7 of IASLC 
staging system. The follow-up interval was every 4–6 months 
within the first 2 years after the operation and then once a 
year according to the NCCN guideline 2011 version 3. This 
study was approved by the Ethics Committee of Shanghai 
Pulmonary Hospital, Tongji University, Shanghai, China and a 
written informed consent was obtained from each participant 
before the initiation of any study-related procedures.
Mutational Analyses
Genomic DNA or RNA was extracted from lung tumors 
as per standard protocols (RNeasy Mini Kit, and QiAamp 
DNA Mini Kit, Qiagen, Hilden, Germany). The isolated RNA 
samples were used for reverse transcription into cDNA using 
Revert Aid First Strand cDNA Synthesis Kit (Fermentas, St 
Leon-Rot, Germany). Either genomic DNA or cDNA were 
used for polymerase chain reaction (PCR) amplification and 
sequencing. EGFR (exons 18–21), HER2 (exons 18–21), 
KRAS (exons 2–3), BRAF (exons 11–15), and the exons 9 and 
20 of PIK3CA were PCR amplified using genomic DNA. Cycle 
sequencing of the purified PCR products was carried out with 
PCR primers using the commercially available ADx Mutation 
Detection Kits (Amory, Xiamen, China). The Ct values used 
to determine if a sample is positive or negative are based on 
extensive validation. Details were seen in previous studies.21–24
Detection of ALK/ROS1/RET Gene 
Fusion in Clinical Specimens
The ALK, ROS1, and RET fusion mRNA was read-
ily detected by PCR with ADxAmoyDx EML4-ALK, ROS1, 
and RET fusion gene detection kit (Amoy Diagnostics Co., 
Ltd, Xiamen, China). In brief, total RNA was extracted with 
QiagenRNeasy FFPE Kit (Cat. No.73504) and the mRNA 
were reverse-transcribed to cDNA at 42°C for 1 hour. β-actin 
was used as the internal control. The real time PCR conditions 
were as follows: an initial denaturation at 95°C for 5 minutes, 
followed by 95°C for 25 seconds, 64°C for 20 seconds, 72°C 
for 20 seconds to ensure the specificity and 31 cycles of 93°C 
for 25 seconds, 60°C for 35 seconds, 72°C for 20 seconds to 
perform the data collection and the sensitivity. The qualitative 
judgment is according to the mutation fluorescence signal. 
Details were seen in our previous studies.24–27
Statistical Analysis
Statistical analysis was carried out with SPSS version 
13.0 (SPSS, Inc., Chicago, IL). Disease-free survival (DFS) 
was defined as the time from the operation to the first doc-
umentation of disease relapse/metastasis or death from any 
cause. Overall survival (OS) was defined as the period from 
the operation to the date of death by any cause, or the date 
when the patient was last known to be alive. All time-to-event 
outcomes were estimated using the Kaplan–Meier method. 
χ2 test or Fisher’s exact test was used to analyze correlations 
between driver genes mutation status with pathological sub-
groups or radiological subtypes. The Kruskal–Wallis test was 
used to determine association significance between continu-
ous variables (i.e., diameter of lesions) and polychotomous 
variables (i.e., radiological subtypes or adenocarcinoma sub-
groups). All the statistical tests were conducted at the two-
sided 0.05 level of significance.
RESULTS
Patient Population
From Jun 2009 to Nov 2012, a total of 35 NSCLC patients 
who had their multiple intrapulmonary nodules resected were 
consecutively collected at the Shanghai Pulmonary Hospital, 
Tongji University, in Shanghai, China. The median age was 60 
years (range, 46–82 years). The proportions of males, never-
smokers, and patients with adenocarcinomas were 34.3%, 
71.4%, and 100%, respectively. Of these, 33 cases had two 
intrapulmonary lesions and two had three pulmonary lesions. 
Imaging examination showed that there were 60 lesions with 
GGN and 12 with solid nodules. None of the enrolled patients 
received neoadjuvant chemotherapy or any other anticancer 
therapy before the operation, whereas 14 patients received 
platinum-based doublet adjuvant chemotherapy. Detailed 
clinical characteristics are listed in Table 1.
Driver Mutation Analysis
Of 72 samples available to perform the mutation analy-
sis, EGFR kinase domain mutations were noticed in 45.8% 
of the tumors (33 of 72; 95% confidence interval [CI]: 
0.4306–0.7361). Among these, 13 were deletions in exon 
19, 18 had L858R missense change, and two were exon 19 
deletion together with L858R mutation (Fig. 1). HER2 muta-
tions were seen in 5.6% of the samples (four of 72; 95% CI: 
0.0278–0.1806), all of which were four amino acids “YVMA” 
insertion mutation in exon 20. Similarly, 4.2% of the samples 
(three of 72; 95% CI: 0.0139–0.1528) had KRAS G12C muta-
tion. 1.9% of the samples (one of 72; 95% CI: 0.0000–0.0972) 
samples had a BRAFV600E mutation (Fig. 1).
EML4-ALK gene fusions were observed in 5.6% of 
tumors (five of 72; 95% CI: 0.0278–0.1806; Fig. 1). Three of 
the fusions were EML4 exon 20 with ALK exon 20 and two 
were EML4 exon 13 with ALK exon 20. Also, 1.9% of the 
samples (one of 72; 95% CI: 0.0000–0.0972) were found to 
have a ROS1 fusion, which was ROS1 exon 34 with TPM3 
exon 8. PIK3CA mutation and RET fusion were not found 
in these samples. Among the tumors with known mutations, 
most were mutually exclusive, except one case harboring both 
EGFR mutation and EML4-ALK fusion (Fig. 1).
Comparison of Driver Mutation Status 
in Different Pulmonary Nodules
The discordant frequency rate of the driver mutation 
distribution was 68.6% (24 of 35) in the whole population, 
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whereas it was 80% (24 of 30) in the patients harbored at 
least one of the detected driver mutations. In one of the two 
cases who had three resected lung lesions, exon 21 L858R 
point mutation, exon 19 deletion, and L858R along with 
ALK fusion was found in the three tumors, respectively. As 
for EGFR gene alone, the discordant rate of driver mutations 
was 45.7% (16 of 35) in the whole population, whereas it was 
72.7% (16 of 22) in patients with at least one sample harbor-
ing EGFR mutation (Table 2).
The Association of Driver 
Mutation with Histology
Seventy-two lesions were included into this analysis, 
including nine adenocarcinoma in situ (AIS), nine minimal 
invasive adenocarcinoma (MIA), and 54 invasive adenocar-
cinoma (IA). The median diameter of the IA lesions was 
1.85 cm, which was significantly longer than 1.08 cm in the 
AIS and 0.90 cm in the MIA subgroup (p < 0.001). The inci-
dence rate of mutation drivers was 44.4% in the AIS subgroup, 
which was not significantly different than 55.6% in the MIA 
subgroup and 70.4% in the IA subgroup (p = 0.257; Table 3).
The Association of Driver Mutation 
with Radiological Subtypes
Imaging examination showed that there were 35 lesions 
with pure GGN, 25 with part-solid GGN, and 12 with solid 
nodule. The median diameter of the solid lesions was 1.40 cm, 
which was similar to 1.35 cm in the pure GGN and 1.68 cm in 
the part-solid GGN (p = 0.541). The incidence rate of driver 
mutations was 50% in the solid lesion subgroup, which was not 
significantly different from 71.4% in the pure GGN subgroup 
and 64% in the part-solid GGN subgroup (p = 0.399; Table 4).
Survival Analysis
As surgical resection is considered as one of the rational 
strategies in managing patients with GGNs,28,29 we also per-
formed survival analysis in all the enrolled 35 patients with a 
median follow-up time of 39.8 months (95% CI: 24.47–52.64). 
Among them, 18 patients (51.4%) were disease free and 32 




Median age, years 60 (46–82)
Sex
  Male 12 (34.3%)
  Female 23 (65.7%)
Performance status (ECOG; %)
  0 22 (62.9%)
  1 13 (37.1%)
Smoking status
  Never-smoker 25 (71.4%)
  Smoker 10 (28.6%)
Pulmonary lesions
  2 33 (94.3%)
  3 2 (5.7%)
Imaging feature of lesions
  One GGN 11 (31.4%)
  Two GGN 23 (65.7%)
  Three GGN 1 (2.9%)
Lymph node metastasis
  N0 30 (85.7%)
  N1 4 (11.4%)
  N2 1 (2.9%)
Operative mode
  Open lobectomy of two lobes 1 (2.9%)
  Open lobectomy and sublobar resection 4 (11.4%)
  VATS lobectomy of two lobes 8 (22.8%)
  VATS lobectomy and sublobar resection 22 (62.9%)
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of Aug 10, 2014. The median DFS and OS for the evaluable 
patients in this study were 41.2 months (95% CI: 35.8–52.6 
months) and “still not reached,” respectively (Fig. 2).
DISCUSSION
In this study, we analyze mutational status in 72 lesions 
from 35 patients presenting with GGN, namely EGFR, KRAS, 
HER2, BRAF, and PIK3CA as well as genes fusions of ALK, 
ROS1, and RET to determine the discrepancy of driver muta-
tions in NSCLC patients with multiple pulmonary nodules. 
To the best of our knowledge, this study represents the first 
comprehensive and concurrent analysis of these known driver 
mutations in a cohort of lung cancer patients with multiple 
lung GGNs. We found a high discordance rate of 68.6% (24 
of 35) in the whole population and 80% (24 of 30) in patients 
harboring at least one of the detected driver mutations.
Intratumor heterogeneity is the existence of different can-
cer clonality in the same patient either because of anatomical 
selection or evolution over time and treatment that has been 
described recently and poses a significant challenge to personal-
ized cancer medicine.30–32 In lung cancer, it was reported that 
activating EGFR mutations were found to display intratumor 
heterogeneity and spatial discordance in 6.3–30% of cases.15,19 
Moreover, patients with multiple pulmonary nodules have a 
significantly higher rate of heterogeneity in EGFR mutations 
compared with extrapulmonary metastasis.15 In our study, we 
focused on patients with multiple lung GGNs and found a driver 
mutation discrepancy as high as 80% in 30 patients who har-
bored at least one genetic alteration. In line with our results, 
Chung et al.12 detected EGFR mutations in 24 NSCLC patients 
who had multiple lung nodules with GGO and also found a high 
discordancy rate of 70.8% (17 of 24). Our results thus are in 
concordance with previous findings and support the hypothesis 
that many multiple GGNs in NSCLC patients seem to arise from 
different primary clones31,32 and therefore warrant different strat-
egies from those with metastatic multiple pulmonary lesions.
However, up to date there is still no consensus regarding 
the optimal management of NSCLC patients with multiple pul-
monary nodules, even though the detection of multiple GGNs 
has become increasingly common with recent advances in 
radiology.6,7,28,33 Chang et al.10 investigated the natural history 
of pure GGO including multiple GGO lesions, and suggested 
that about 90% of the screening-detected pure GGO lung nod-
ules did not grow during long-term follow-up in subjects with 
no history of malignancy. Similarly, Chung et al. observed 
multiple pure GGO lesions in patients with bronchiolo-alveolar 
carcinoma remained without surgical resection and found 
there was no change in their size or features after a median 
follow-up period of 40.3 months. However, for patients with 
part-solid GGN lesion, Asamura et al.29 suggested that patients 
should be interpreted as surgical candidates, even with multi-
ple lesions. Our previous case report showed that when opera-
tion is feasible, it should be considered as a proper option for 
patients with heterogeneous bilateral quadruple pulmonary 
nodules.28 In this study, all of the enrolled patients had at least 
one GGN and had their nodules resected simultaneously, the 
median DFS was 44.2 months (95% CI: 35.8–52.6months) 
TABLE 2.  Comparison of Driver Mutation Status in Matched Tumors from 35 Patients with Multiple Intrapulmonary Nodules
Number No. of Alternation No. of Consistency* Discordant Rate
Whole population 35 24 11 68.4%
Patients with detectable mutations 30 24 6 80%






(cm, Range) EGFR ALK KRAS HER2 BRAF ROS1 Negative
AIS 9 1.08 (0.74–1.60) 2 1 1 0 0 0 5
MIA 9 0.90 (0.50–1.20) 2 1 0 2 0 0 4
IA 54 1.85 (0.64–3.00) 29 3 2 2 1 1 16
p valuea NA <0.001 0.058 0.764 0.471 0.059 0.844 0.844 0.257
aStatistical analysis was performed between driver mutations or diameter of the lesions with adenocarcinoma subgroups.
AIS, adenocarcinoma in situ; MIA, minimal invasive adenocarcinoma; IA, invasive adenocarcinoma.
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and OS has not been reached yet, therefore supporting the idea 
that GGN lesions may be considered as primary tumors and 
resection is a proper option for this subgroup.
In this study, we also compared the driver mutations in 
different subgroups of adenocarcinoma according to the new 
classification. As we know, KRAS and p53 mutations have been 
detected in precursor lesions of adenocarcinoma and squamous 
cell carcinoma, respectively.34,35 Also, EGFR mutations were 
found in atypical adenomatous hyperplasia and had a similar inci-
dence rate in bronchioloalveolar carcinoma and adenocarcinoma, 
supporting the observation that EGFR gene mutations occur in 
an early stage of pulmonary adenocarcinoma development.36,37 In 
line with these results, we found EGFR and KRAS mutations 
in those early lesions diagnosed as AIS. Interestingly, we also 
detected EML4-ALK fusion in an AIS lesion, a very early stage 
of pulmonary adenocarcinoma, which suggests that EML4-ALK 
fusion protein may also play an important role in tumor initiation 
and early stage of development much like the oncogenes EGFR 
or KRAS.38,39 As far as we know, this is the first time to report the 
detection of EML4-ALK in carcinoma in situ.
There are several limitations of this study that have to be 
considered. First, the sample size is relatively small, and the 
retrospective nature of the study may induce a selection bias. 
Second, the information obtained using the eight oncogenic 
driver genes may only represent a part of the picture because 
whole genome or exome sequencing was not used in this 
study. Third, a metastatic tumor may also be different from its 
primary at a genetic level because of progressive accumula-
tion of genetic alterations in some cases.32 Fourth, the survival 
data might be over-optimistic because the sizes of GGN are in 
the early stage and a part of them received adjuvant chemo-
therapy. Thus, a larger prospective study is needed to validate 
our findings.
In conclusion, we found a high level of intertumor dis-
crepancy of somatic driver mutations in patients with multiple 
GGNs. The high discrepancy suggests that many of these 
tumors likely have developed as independent primaries rather 
than metastatic disease. We observed a favorable prognosis 
after surgical resection of those lesions, supporting the strat-
egy that multiple GGNs in NSCLC patients might be consid-
ered as primary tumors and resection might be a proper option 
for this subgroup.
ACKNOWLEDGMENTS
This study was supported in part by grants from the 
National Science Foundation of China (No. 81172101 & 
No. 81201707), projects of the Science and Technology 
Commission of Shanghai Municipality (No. 11JC1411300, 
No. 12ZR1426000, No. shdc12012111, and No. 13411950104) 
and key project of Shanghai Municipal Commission of Health 
and Family Planning (No. 2013zyjb0401).
REFERENCES
 1. Detterbeck FC, Jones DR, Kernstine KH, Naunheim KS; American 
College of Physicians. Lung cancer. Special treatment issues. Chest 
2003;123:244S–258S.
 2. Kozower BD, Larner JM, Detterbeck FC, Jones DR. Special treatment 
issues in non-small cell lung cancer: Diagnosis and management of lung 
cancer, 3rd ed: American College of Chest Physicians evidence-based 
clinical practice guidelines. Chest 2013;143:e369S–e399S.
 3. Ferguson MK. Synchronous primary lung cancers. Chest 
1993;103:398S–400S.
 4. Zhang Y, Hu H, Wang R, et al. Synchronous non-small cell lung cancers: 
Diagnostic yield can be improved by histologic and genetic methods. Ann 
Surg Oncol 2014;21:4369–4374.
 5. Murphy SJ, Aubry MC, Harris FR, et al. Identification of independent pri-
mary tumors and intrapulmonary metastases using DNA rearrangements 
in non-small-cell lung cancer. J Clin Oncol 2014;32:4050–4058.
 6. Godoy MC, Naidich DP. Subsolid pulmonary nodules and the spectrum 
of peripheral adenocarcinomas of the lung: Recommended interim guide-
lines for assessment and management. Radiology 2009;253:606–622.
 7. Detterbeck FC, Homer RJ. Approach to the ground-glass nodule. Clin 
Chest Med 2011;32:799–810.
 8. Sim HJ, Choi SH, Chae EJ, et al. Surgical management of pulmo-
nary adenocarcinoma presenting as a pure ground-glass nodule. Eur J 
Cardiothorac Surg 2014;46:632–636; discussion 636.
 9. Kim TJ, Goo JM, Lee KW, Park CM, Lee HJ. Clinical, pathological and 
thin-section CT features of persistent multiple ground-glass opacity 
nodules: Comparison with solitary ground-glass opacity nodule. Lung 
Cancer 2009;64:171–178.
 10. Chang B, Hwang JH, Choi YH, et al. Natural history of pure ground-
glass opacity lung nodules detected by low-dose CT scan. Chest 
2013;143:172–178.
 11. Arai J, Tsuchiya T, Oikawa M, et al. Clinical and molecular analysis of 
synchronous double lung cancers. Lung Cancer 2012;77:281–287.
 12. Chung JH, Choe G, Jheon S, et al. Epidermal growth factor receptor 
mutation and pathologic-radiologic correlation between multiple lung 
nodules with ground-glass opacity differentiates multicentric origin from 
intrapulmonary spread. J Thorac Oncol 2009;4:1490–1495.
 13. Matsumoto S, Takahashi K, Iwakawa R, et al. Frequent EGFR muta-
tions in brain metastases of lung adenocarcinoma. Int J Cancer 
2006;119:1491–1494.
 14. Munfus-McCray D, Harada S, Adams C, et al. EGFR and KRAS mutations 
in metastatic lung adenocarcinomas. Hum Pathol 2011;42:1447–1453.
 15. Chen ZY, Zhong WZ, Zhang XC, et al. EGFR mutation heterogeneity and 
the mixed response to EGFR tyrosine kinase inhibitors of lung adenocar-
cinomas. Oncologist 2012;17:978–985.
 16. Park S, Holmes-Tisch AJ, Cho EY, et al. Discordance of molecular 
biomarkers associated with epidermal growth factor receptor pathway 
between primary tumors and lymph node metastasis in non-small cell 




(cm, range) EGFR ALK KRAS HER2 BRAF ROS1 Negative
Pure GGN 35 1.35 (0.50–3.00) 18 2 2 2 1 0 10
Part-solid GGN 25 1.68 (0.74–2.90) 13 1 1 1 0 0 9
Solidary nodule 12 1.40 (0.83–3.00) 2 2 0 1 0 1 6
p valuea NA 0.541 0.085 0.337 0.693 0.864 0.585 0.079 0.399
aStatistical analysis was performed between driver mutations or diameter of the lesions with radiological subtypes.
GGN, ground-glass nodules.
783Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 5, May 2015 High Discrepancy of Driver Mutations
 17. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M. EGFR/KRAS/
BRAF mutations in primary lung adenocarcinomas and corresponding 
locoregional lymph node metastases. Clin Cancer Res 2009;15:4554–4560.
 18. Girard N, Deshpande C, Azzoli CG, et al. Use of epidermal growth fac-
tor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation test-
ing to define clonal relationships among multiple lung adenocarcinomas: 
Comparison with clinical guidelines. Chest 2010;137:46–52.
 19. Bai H, Wang Z, Wang Y, et al. Detection and clinical significance of 
intratumoral EGFR mutational heterogeneity in Chinese patients with 
advanced non-small cell lung cancer. PLoS One 2013;8:e54170.
 20. Travis WD, Brambilla E, Noguchi M, et al. International association for 
the study of lung cancer/American thoracic society/European respiratory 
society international multidisciplinary classification of lung adenocarci-
noma. J Thorac Oncol 2011;6:244–285.
 21. Ren S, Su C, Wang Z, et al. Epithelial phenotype as a predictive marker 
for response to EGFR-TKIs in non-small cell lung cancer patients with 
wild-type EGFR. Int J Cancer 2014;135:2962–2971.
 22. Li W, Ren S, Li J, et al. T790M mutation is associated with better efficacy 
of treatment beyond progression with EGFR-TKI in advanced NSCLC 
patients. Lung Cancer 2014;84:295–300.
 23. Ren S, Kuang P, Zheng L, et al. Analysis of driver mutations in female 
non-smoker Asian patients with pulmonary adenocarcinoma. Cell 
Biochem Biophys 2012;64:155–160.
 24. Ren S, Chen X, Kuang P, et al. Association of EGFR mutation or ALK rear-
rangement with expression of DNA repair and synthesis genes in never-smoker 
women with pulmonary adenocarcinoma. Cancer 2012;118:5588–5594.
 25. Cai W, Li X, Su C, et al. ROS1 fusions in Chinese patients with non-
small-cell lung cancer. Ann Oncol 2013;24:1822–1827.
 26. Cai W, Su C, Li X, et al. KIF5B-RET fusions in Chinese patients with 
non-small cell lung cancer. Cancer 2013;119:1486–1494.
 27. Ren S, Hirsch FR, Varella-Garcia M, et al. Atypical negative ALK break-
apart FISH harboring a crizotinib-responsive ALK rearrangement in non-
small-cell lung cancer. J Thorac Oncol 2014;9:e21–e23.
 28. Yang Y, Wang H, Liu M, Jiang G. Surgical algorithm for heterogeneous 
bilateral quadruple pulmonary nodules. Interact Cardiovasc Thorac Surg 
2013;17:892–894.
 29. Asamura H, Suzuki K, Watanabe S, Matsuno Y, Maeshima A, Tsuchiya 
R. A clinicopathological study of resected subcentimeter lung cancers: A 
favorable prognosis for ground glass opacity lesions. Ann Thorac Surg 
2003;76:1016–1022.
 30. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and 
branched evolution revealed by multiregion sequencing. N Engl J Med 
2012;366:883–892.
 31. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the 
clinic. Nature 2013;501:355–364.
 32. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor 
heterogeneity: Seeing the wood for the trees. Sci Transl Med 
2012;4:127ps10.
 33. Kim HK, Choi YS, Kim J, Shim YM, Lee KS, Kim K. Management of 
multiple pure ground-glass opacity lesions in patients with bronchioloal-
veolar carcinoma. J Thorac Oncol 2010;5:206–210.
 34. Li ZH, Zheng J, Weiss LM, Shibata D. c-k-ras and p53 muta-
tions occur very early in adenocarcinoma of the lung. Am J Pathol 
1994;144:303–309.
 35. Hirano T, Franzén B, Kato H, Ebihara Y, Auer G. Genesis of squamous 
cell lung carcinoma. Sequential changes of proliferation, DNA ploidy, 
and p53 expression. Am J Pathol 1994;144:296–302.
 36. Ikeda K, Nomori H, Ohba Y, et al. Epidermal growth factor receptor 
mutations in multicentric lung adenocarcinomas and atypical adenoma-
tous hyperplasias. J Thorac Oncol 2008;3:467–471.
 37. Yoo SB, Chung JH, Lee HJ, Lee CT, Jheon S, Sung SW. Epidermal 
growth factor receptor mutation and p53 overexpression during the mul-
tistage progression of small adenocarcinoma of the lung. J Thorac Oncol 
2010;5:964–969.
 38. Sartori G, Cavazza A, Bertolini F, et al. A subset of lung adenocarcino-
mas and atypical adenomatous hyperplasia-associated foci are genotypi-
cally related: An EGFR, HER2, and K-ras mutational analysis. Am J Clin 
Pathol 2008;129:202–210.
 39. Soda M, Choi YL, Enomoto M, et al. Identification of the transform-
ing EML4-ALK fusion gene in non-small-cell lung cancer. Nature 
2007;448:561–566.
